TGI-17a / TG ImmunoPharma - LARVOL DELTA

TGI-17a: A potential best-in-class PD-1/IL-2α-biascytokine fusion protein (AACR 2026) - "In toxicity studies, TGI-17a was well-tolerated at doses up to 40 mg/kg (IV, twice weekly) in mice, whereas the competitor caused lethality at 5 mg/kg.In the in vivo efficacy studies, TGI-17a demonstrated superior anti-tumor activity compared to the PD-1 antibody pembrolizumab in both MC38 and B16F10 models. These results indicate that TGI-17a, a potential best-in-class PD-1/IL-2α-bias bispecific antibody fusion protein, possesses compelling anti-tumor efficacy and a favorable safety profile in preclinical models. This robust evidence supports its further clinical development as a promising therapeutic candidate for pan-cancer applications."

Oncology • CD8 • PD-1 • STAT5